GSK R&D chief Hal Barron (left) and Vir CEO George Scangos
GlaxoSmithKline bets another $345M cash on Vir, expanding Covid-19 partnership to flu, RSV and other viruses
After GlaxoSmithKline and Vir signed their $250 million partnership last April, they quickly ran into a problem.
The two were supposed to be working …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
